Skip to main content
TipRanks
Go Ultimate75% OFF

Amoeba SA (0RAE) Share Price & Analysis

0 Followers

0RAE Stock Chart & Stats

€0.30-€0.02(-4.78%)
At close: 4:30 PM GMT
€0.25€0.5Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 0.30 - EUR 0.30
52-Week Range
EUR 0.25 - EUR 1.12
Previous Close
EUR 0.31
Volume
N/A
Average Volume (3M)
5,668
Market Cap
EUR 36.23M
Enterprise Value
EUR 78.49M
Total Cash (Recent Filing)
EUR 5.52M
Total Debt (Recent Filing)
EUR 12.67M
Price to Earnings (P/E)
―
Beta
1.59
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Biological Platform

A proprietary biological platform gives Amoéba a differentiated basis for developing products in markets seeking lower-impact microbial control and bio-based performance. If regulatory and commercial execution progress, the platform may support multiple products and create longer-term intellectual-property-led growth opportunities.

Multiple Application Markets

Exposure to both agricultural inputs and industrial applications broadens the potential addressable market beyond a single product category. This application diversity can provide strategic flexibility, allowing the company to prioritize the regulatory or commercial pathway with the strongest adoption potential over the coming quarters.

Some Improvement In Losses And Cash Flow

Although performance remains weak, the reported narrowing of losses versus 2023 and improvement in free cash flow versus 2024 indicate some movement away from the worst historical levels. Sustaining that direction could gradually improve funding needs and provide a more credible basis for future operating leverage.

Bears Say

Revenue Collapse

Revenue falling to zero demonstrates that the company has not yet established dependable commercial scale. Without recurring sales, fixed research, regulatory and operating costs remain difficult to absorb, limiting visibility into future margins and making the business highly dependent on successful product commercialization.

Persistent Unprofitable Operations

Repeated operating and net losses show that the current business model has not reached sustainable profitability. Continued negative earnings can consume available resources, restrict reinvestment choices, and leave future value creation dependent on achieving meaningful revenue growth and improved gross economics.

Negative Equity And Rising Debt

Negative equity combined with materially higher debt weakens financial resilience and reduces flexibility to fund development internally. The balance-sheet deterioration increases reliance on refinancing or new funding, while declining assets and leverage make execution setbacks more consequential for shareholders and creditors.

Amoeba SA News

0RAE FAQ

What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest share price was €0.25 and its highest was €1.12 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €36.23M.
When is Amoeba SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Sep 24, 2026. The company reported -€0.095 earnings per share for the quarter.
Is Amoeba SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 129,179,120 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.095 in its last earnings report. Following the earnings report the stock price went down -7.905%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in GB:0RAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology